Skip Navigation
Skip to contents

Intest Res : Intestinal Research

IMPACT FACTOR

Articles

Page Path
HOME > Intest Res > Volume 24(1); 2026 > Article
Editorial
IBD
Interpreting vedolizumab persistence: lessons from real-world trajectories in ulcerative colitis
Jung Min Moonorcid
Intestinal Research 2026;24(1):3-5.
DOI: https://doi.org/10.5217/ir.2025.00289
Published online: January 28, 2026

Center for Health Promotion and Optimal Aging, Seoul National University Hospital, Seoul, Korea

Correspondence to Jung Min Moon, Center for Health Promotion and Optimal Aging, Seoul National University Hospital, 101 Daehak-ro, Jongno-gu, Seoul 03080, Korea. E-mail: moon_jm@naver.com
• Received: November 17, 2025   • Revised: December 1, 2025   • Accepted: December 7, 2025

© 2026 Korean Association for the Study of Intestinal Diseases.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

prev next
  • 501 Views
  • 25 Download
See the article "Factors affecting 1-year persistence with vedolizumab for ulcerative colitis: a multicenter, retrospective real-world study" on page 64.
Vedolizumab (VDZ), a humanized monoclonal antibody targeting α4β7 integrin, has become an established and well-tolerated therapeutic option for ulcerative colitis (UC) following its approval based on the phase III GEMINI trial [1,2]. However, evidence on long-term treatment persistence in real-world settings, especially across Asian populations, remains limited. In this issue of Intestinal Research, the multicenter retrospective study by Kobayashi et al. [3] provides valuable insights into 1-year persistence with VDZ and identifies clinical predictors of treatment discontinuation.
Kobayashi et al. [3] report outcomes from a large multicenter Japanese cohort of 370 patients with UC, with a median follow-up of 53 weeks and 1-year persistence rate of 64.5%. Despite the retrospective design, the large sample size and relatively long follow-up observation period strengthen the reliability of the results. Primary nonresponse accounted for 42.0% and among patients who initially achieved remission, 12.5% discontinued due to loss of response (LOR). Multivariable analysis revealed that concomitant tacrolimus use (odds ratio [OR], 2.76) and shorter disease duration (OR, 0.33 for ≥7.8 years compared with <7.8 years) were associated with discontinuation due to LOR. In contrast, prior anti-tumor necrosis factor (anti-TNF) exposure, age, and baseline disease severity were not associated with LOR. Importantly, persistence was consistent across both biologic-naive and previously exposed patients, underscoring the broad utility of VDZ in clinical practice.
The results align with other real-world data. Despite inherent limitations of claims-based studies, a large Japanese analysis demonstrated 12-month persistence rates of 69.7% for VDZ; lower than ustekinumab (84.0%), but comparable to tofacitinib (61.6%), infliximab (62.9%), adalimumab (57.6%) and golimumab (54.9%) [4]. Likewise, Scottish real-world data showed VDZ persistence of 80.7% at 1 year, gradually declining to 47.9% over 5 years [5]. Viewed collectively, this Japanese multicenter study suggests VDZ persistence in Asian populations is broadly comparable—albeit slightly lower—to Western cohorts, and comparable to other advanced biologics.
Beyond persistence related to efficacy, VDZ is widely recognized for its favorable safety profile, attributable to its gut-selective mechanism. This characteristic often makes VDZ a preferred biologic option for elderly patients in many countries. These real-world data analyses by Kobayashi et al. [3] support comparable persistence across age groups. In another study by a large Japanese claims dataset, patients prescribed VDZ were older than those receiving anti-TNF agents, yet persistence remained independent of age [4]. This is consistent with the post hoc analysis of GEMINI, which demonstrated no significant age-related differences in safety or efficacy [6].
Whereas immunogenicity is the most common cause of secondary LOR in anti-TNF agents, the mechanisms underlying the low immunogenicity of VDZ remain uncertain. In this study, 12.5% experienced LOR, yet concomitant immunomodulatory use, prior anti-TNF exposure, and disease severity were not significantly associated with LOR. The recent randomized controlled trial suggested a potential benefit of thiopurine combination for achieving deeper remission in selected patients, although thiopurines did not affect VDZ trough levels [7]. Why certain patients develop secondary LOR remains unclear and warrants further investigation.
Sequencing UC therapies has become increasingly complex with the expanding array of novel biologics and small molecules. The present study demonstrated that VDZ persistence was consistent across both biologic naive and exposed patients. Combined with findings from another study by the same group showing higher week 2 remission rates among biologic-naive patients, these data support the potential role of VDZ as a first-line biologic agent [8]. Western data echo this trend. In a Scottish cohort, prior exposure to 1 or more biologics significantly increased the risk of treatment failure (hazard ratio [HR], 1.54 for 1 prior agent; HR, 2.12 for ≥2). Furthermore, a real-world Australian cohort study suggested that first-line VDZ had superior persistence compared to infliximab, but VDZ did not compromise the efficacy of subsequent infliximab therapy [9].
A particularly noteworthy contribution of the current study is the identification of 2 predictors of LOR: tacrolimus use and short disease duration. Tacrolimus is typically concomitantly used in severe, steroid-refractory UC, and patients transitioning directly from calcineurin inhibitors to VDZ may represent a difficult-to-treat subgroup with unstable disease behavior. This finding adds a nuance that clinicians be cautious when switching such patients to VDZ and may need to carefully anticipate early LOR or consider alternative early strategies.
The observation that patients with disease duration <1 year exhibited a markedly high LOR rate (32.0%) is especially intriguing. This challenges the conventional belief that early biologic intervention uniformly improves outcomes. Instead, it suggests the existence of a subset of newly diagnosed patients with a biologically aggressive phenotype that responds poorly to VDZ alone. This interpretation is reinforced by a companion analysis from the same group showing that patients with early primary nonresponse to anti-TNF therapy—particularly those who failed within 3 months—also had poor response to VDZ [10]. Taken together, these findings imply the presence of a “biologic-refractory phenotype” defined by short disease duration, rapid anti-TNF failure, and need for tacrolimus, for whom VDZ may be less effective.
Several limitations should be considered. As with all retrospective studies, unmeasured confounding cannot be excluded. Differences in policy environments—including availability of subcutaneous injection and dose intensification strategies— limit cross-regional comparability. In Japan, dose intensification is not reimbursed by the insurance system, thus the slightly lower 1-year persistence compared to other reference may be explained. Moreover, data on the transition from intravenous to subcutaneous administration, increasingly relevant in modern clinical practice, were not available.
The real-world data presented by Kobayashi et al. [3] provide a pivotal clinical message: the success of VDZ is shaped not only by its mechanism of action but also by the patient’s prior therapeutic trajectory. Short disease duration to considering biologic agent, early anti-TNF failure, and concomitant tacrolimus characterize a phenotype of heightened treatment resistance in which VDZ may be less durable. Conversely, patients with stable disease courses—even if previously biologic-experienced—can achieve sustained benefit. Integrating these insights into clinical decision-making may enhance patient selection, personalize therapeutic strategies, and ultimately guide future treatment algorithms.

This manuscript was edited for clarity with assistance from ChatGPT (OpenAI). All final interpretations and conclusions are the authors’ own.

Funding Source

The author received no financial support for the research, authorship, and/or publication of this article.

Conflict of Interest

Moon JM is an editorial board member of the journal but was not involved in the peer reviewer selection, evaluation, or decision process of this article. No other potential conflicts of interest relevant to this article were reported.

Data Availability Statement

Not applicable.

Author Contributions

Writing and approval of the final manuscript: Moon JM.

  • 1. Loftus EV, Colombel JF, Feagan BG, et al. Long-term efficacy of vedolizumab for ulcerative colitis. J Crohns Colitis 2017;11:400–411.ArticlePubMed
  • 2. Song EM, Na SY, Hong SN, Ng SC, Hisamatsu T, Ye BD. Treatment of inflammatory bowel disease-Asian perspectives: the results of a multinational web-based survey in the 8th Asian Organization for Crohn’s and Colitis meeting. Intest Res 2023;21:339–352.ArticlePubMedPMCPDF
  • 3. Kobayashi T, Hisamatsu T, Motoya S, et al. Factors affecting 1-year persistence with vedolizumab for ulcerative colitis: a multicenter, retrospective real-world study. Intest Res 2026;24:64–75.ArticlePubMedPDF
  • 4. Matsuoka K, Nakajo K, Kawamura S, et al. Persistence of advanced therapies in patients with inflammatory bowel disease: retrospective cohort study using a large healthcare claims database in Japan. Intest Res 2025;23:358–371.ArticlePubMedPMCPDF
  • 5. Gros B, Ross H, Nwabueze M, et al. Long-term outcomes and predictors of vedolizumab persistence in ulcerative colitis. Therap Adv Gastroenterol 2024;17:17562848241258372.ArticlePubMedPMCPDF
  • 6. Yajnik V, Khan N, Dubinsky M, et al. Efficacy and safety of vedolizumab in ulcerative colitis and Crohn’s disease patients stratified by age. Adv Ther 2017;34:542–559.ArticlePubMedPMCPDF
  • 7. Pudipeddi A, Paramsothy S, Kariyawasam V, et al. Effects of thiopurine withdrawal on vedolizumab-treated patients with ulcerative colitis: a randomized controlled trial. Clin Gastroenterol Hepatol 2024;22:2299–2308.ArticlePubMed
  • 8. Kobayashi T, Hisamatsu T, Motoya S, et al. Week 2 remission with vedolizumab as a predictor of long-term remission in patients with ulcerative colitis: a multicenter, retrospective, observational study. Intest Res 2025;Jul 14 [Epub]. https://doi.org/10.5217/ir.2025.00047.Article
  • 9. Pudipeddi A, Ko Y, Paramsothy S, Leong RW. Vedolizumab has longer persistence than infliximab as a first-line biological agent but not as a second-line biological agent in moderate-to-severe ulcerative colitis: real-world registry data from the Persistence Australian National IBD Cohort (PANIC) study. Therap Adv Gastroenterol 2022;15:17562848221080793.ArticlePubMedPMCPDF
  • 10. Kobayashi T, Hisamatsu T, Motoya S, et al. The duration of prior anti-tumor necrosis factor agents is associated with the effectiveness of vedolizumab in patients with ulcerative colitis: a real-world multicenter retrospective study. Intest Res 2025;Jun 4 [Epub]. https://doi.org/10.5217/ir.2024.00126.Article

Figure & Data

REFERENCES

    Citations

    Citations to this article as recorded by  

      • PubReader PubReader
      • ePub LinkePub Link
      • Cite
        CITE
        export Copy Download
        Close
        Download Citation
        Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

        Format:
        • RIS — For EndNote, ProCite, RefWorks, and most other reference management software
        • BibTeX — For JabRef, BibDesk, and other BibTeX-specific software
        Include:
        • Citation for the content below
        Interpreting vedolizumab persistence: lessons from real-world trajectories in ulcerative colitis
        Intest Res. 2026;24(1):3-5.   Published online January 28, 2026
        Close
      • XML DownloadXML Download
      Interpreting vedolizumab persistence: lessons from real-world trajectories in ulcerative colitis
      Interpreting vedolizumab persistence: lessons from real-world trajectories in ulcerative colitis

      Intest Res : Intestinal Research
      Close layer
      TOP